Literature DB >> 25736046

Is It Too Much of a Good Thing? A New Era in Phosphate Binder Therapy in ESRD.

Wajeh Y Qunibi1.   

Abstract

Entities:  

Keywords:  anemia; hemodialysis; phosphate binders

Mesh：

Substances：

Year:  2015        PMID： 25736046      PMCID： PMC4587707          DOI： 10.1681/ASN.2015020135

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN： 1046-6673            Impact factor:   10.121


× No keyword cloud information.
  17 in total

1.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2006-05       Impact factor: 8.860

2.  Commentary on 'The DOPPS practice monitor for U.S. dialysis care: update on trends in anemia management 2 years into the bundle': iron(y) abounds 2 years later.

Authors:  Daniel E Weiner; Wolfgang C Winkelmayer
Journal:  Am J Kidney Dis       Date:  2013-12       Impact factor: 8.860

3.  Ferric citrate controls phosphorus and delivers iron in patients on dialysis.

Authors:  Julia B Lewis; Mohammed Sika; Mark J Koury; Peale Chuang; Gerald Schulman; Mark T Smith; Frederick C Whittier; Douglas R Linfert; Claude M Galphin; Balaji P Athreya; A Kaldun Kaldun Nossuli; Ingrid J Chang; Samuel S Blumenthal; John Manley; Steven Zeig; Kotagal S Kant; Juan Jose Olivero; Tom Greene; Jamie P Dwyer
Journal:  J Am Soc Nephrol       Date:  2014-07-24       Impact factor: 10.121

4.  Data from the Dialysis Outcomes and Practice Patterns Study validate an association between high intravenous iron doses and mortality.

Authors:  George R Bailie; Maria Larkina; David A Goodkin; Yun Li; Ronald L Pisoni; Brian Bieber; Nancy Mason; Lin Tong; Francesco Locatelli; Mark R Marshall; Masaaki Inaba; Bruce M Robinson
Journal:  Kidney Int       Date:  2014-07-30       Impact factor: 10.612

5.  Ferric Citrate Reduces Intravenous Iron and Erythropoiesis-Stimulating Agent Use in ESRD.

Authors:  Kausik Umanath; Diana I Jalal; Barbara A Greco; Ebele M Umeukeje; Efrain Reisin; John Manley; Steven Zeig; Dana G Negoi; Anand N Hiremath; Samuel S Blumenthal; Mohammed Sika; Robert Niecestro; Mark J Koury; Khe-Ni Ma; Tom Greene; Julia B Lewis; Jamie P Dwyer
Journal:  J Am Soc Nephrol       Date:  2015-03-03       Impact factor: 10.121

6.  Correction of anemia with epoetin alfa in chronic kidney disease.

Authors:  Ajay K Singh; Lynda Szczech; Kezhen L Tang; Huiman Barnhart; Shelly Sapp; Marsha Wolfson; Donal Reddan
Journal:  N Engl J Med       Date:  2006-11-16       Impact factor: 91.245

7.  A 12-week, double-blind, placebo-controlled trial of ferric citrate for the treatment of iron deficiency anemia and reduction of serum phosphate in patients with CKD Stages 3-5.

Authors:  Geoffrey A Block; Steven Fishbane; Mariano Rodriguez; Gerard Smits; Shay Shemesh; Pablo E Pergola; Myles Wolf; Glenn M Chertow
Journal:  Am J Kidney Dis       Date:  2014-11-04       Impact factor: 8.860

8.  Medicare program; end-stage renal disease prospective payment system. Final rule.

Authors: 
Journal:  Fed Regist       Date:  2010-08-12

9.  A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease.

Authors:  Marc A Pfeffer; Emmanuel A Burdmann; Chao-Yin Chen; Mark E Cooper; Dick de Zeeuw; Kai-Uwe Eckardt; Jan M Feyzi; Peter Ivanovich; Reshma Kewalramani; Andrew S Levey; Eldrin F Lewis; Janet B McGill; John J V McMurray; Patrick Parfrey; Hans-Henrik Parving; Giuseppe Remuzzi; Ajay K Singh; Scott D Solomon; Robert Toto
Journal:  N Engl J Med       Date:  2009-10-30       Impact factor: 91.245

10.  A phase III study of the efficacy and safety of a novel iron-based phosphate binder in dialysis patients.

Authors:  Jürgen Floege; Adrian C Covic; Markus Ketteler; Anjay Rastogi; Edward M F Chong; Sylvain Gaillard; Laura J Lisk; Stuart M Sprague
Journal:  Kidney Int       Date:  2014-03-19       Impact factor: 10.612
View more
  1 in total

Review 1.  Iatrogenic Iron Overload in Dialysis Patients at the Beginning of the 21st Century.

Authors:  Guy Rostoker; Nosratola D Vaziri; Steven Fishbane
Journal:  Drugs       Date:  2016-05       Impact factor: 9.546
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.